Premium
The Expanding Role of Angiotensin Converting Enzyme Inhibitors in the Management of Hypertension
Author(s) -
Burris James F.
Publication year - 1995
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1002/j.1552-4604.1995.tb04070.x
Subject(s) - quinapril , ramipril , tolerability , benazepril , captopril , angiotensin converting enzyme , medicine , pharmacology , bradykinin , ace inhibitor , enzyme inhibitor , enzyme , chemistry , blood pressure , adverse effect , biochemistry , receptor
Angiotensin converting enzyme (ACE) inhibitors are increasingly important in antihypertensive therapy because of their efficacy, tolerability, and specific benefits in subsets of patients. They are pharmacologically diverse. Whereas most benefits have been proven with older agents (captopril, enalopril), newer agents, such as benazepril, quinapril, and ramipril, offer potential advantages that remain to be proven.